文献速递类风湿关节炎

依那西普原研药与依那西普生物类似药作为首个生物制剂治疗类风湿关节炎的比较:BSRBR-RA研究结果

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

基于英国类风湿关节炎生物制剂注册队列(BSRBR-RA)中2010年起启动依那西普治疗的1806例生物制剂初治类风湿关节炎患者,比较依那西普原研药(1009例)与生物类似药(797例)的疗效。6个月和12个月时两组DAS28缓解率和EULAR反应率相似,原研药组与生物类似药组1年药物留存率分别为71%和76%,停药可能性无差异。

要点

  • 生物制剂初治RA患者中,依那西普原研药与生物类似药6个月和12个月DAS28缓解率及EULAR反应率相似。
  • 原研药组71%、生物类似药组76%的患者在1年时仍维持治疗,原研药组停药可能性不高于生物类似药组。
  • 随访期间19%的原研药组患者转换为依那西普生物类似药,转换时进行删失处理。

核心结论

  • 在生物制剂初治RA患者中,依那西普原研药与生物类似药在真实世界数据中的疗效相似,6个月和12个月治疗后的药物留存率和疾病活动度在两组间相似。

研究设计与样本

  • 基于英国风湿病学会类风湿关节炎生物制剂注册(BSRBR-RA)队列研究,纳入2010年起启动依那西普治疗的生物制剂初治RA患者1806例,其中原研药组1009例、生物类似药组797例。
  • 采用Kaplan-Meier和Cox回归评估药物留存率,多重插补处理缺失数据,倾向性评分十分位调整控制适应证混杂。

主要发现

  • 6个月和12个月时,原研药组与生物类似药组达到DAS28缓解和EULAR反应的患者比例相似。
  • 原研药组1年药物留存率为71%,生物类似药组为76%,原研药组停药可能性不高于生物类似药组。
  • 随访期间19%的原研药组患者转换为依那西普生物类似药,转换时进行删失处理。

关键数值与推荐

  • 主要结局为6个月和12个月的DAS28缓解、EULAR反应及功能最小临床重要差异。
  • 药物留存率采用Kaplan-Meier和Cox回归评估,并分析治疗退出原因。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Etanercept biosimilars show comparable efficacy to their originators among biologic-naïve patients with RA in randomized controlled trials. Nationwide guidelines have obligated prescribing of etanercept biosimilars from 2016, resulting in significant cost savings. This analysis aimed to compare the effectiveness of etanercept originator vs etanercept biosimilar amongst biologic-naïve RA patients treated in routine clinical practice in the UK. METHODS: Biologic-naïve RA patients starting etanercept in the British Society for Rheumatology Biologics Register in Rhematoid Arthritis (BSRBR-RA) cohort study from 2010 were included. Data collected at start of therapy includes patient demographics and disease activity. Follow-up data includes changes in disease activity and anti-rheumatic therapy. Six- and 12-month primary outcomes include DAS for 28-joints (DAS28) remission, EULAR response and minimal clinically important difference in function. Etanercept drug survival was assessed using Kaplan-Meier and Cox regression, including reasons for treatment withdrawal. Multiple imputation accounted for missing data. Propensity-decile adjustment was used to account for confounding by indication. RESULTS: A total of 1806 biologic-naïve RA patients started etanercept: 1009 originator, 797 biosimilar. At 6 and 12 months, the proportion of patients achieving DAS28 remission and EULAR response were similar between treatments. During follow-up, 19% of originator patients switched onto etanercept biosimilar. Patients were censored at time of switch. Patients on originator were no more likely to stop therapy vs biosimilar; 71% of originator and 76% of biosimilar patients remained on therapy at 1 year. CONCLUSIONS: In one of the largest analyses of patients with RA, biologic-naïve RA patients treated with etanercept originator showed similar outcomes vs biosimilar using real-world data. Drug survival, and disease activity after 6 and 12 months of therapy, was similar between cohorts.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Kearsley-Fleet L, Rokad A, Tsoi MF, et al. Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA. Rheumatology (Oxford). 2023. PMID: 36943379. doi:10.1093/rheumatology/kead127

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。